| Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. | |
| | |
MedLine Citation:
|
PMID: 19617847 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: By December 2007, over 48,000 persons had initiated antiretroviral treatment (ART) at 171 clinics in Rwanda. Assessing national ART program outcomes is essential to determine whether programs have the desired impact. METHODS: We conducted a retrospective cohort study to assess key 6- and 12-month outcomes among a nationally representative, stratified, random sample of 3194 adults (> or =15 years) who initiated ART from January 1, 2004, through December 31, 2005. FINDINGS: At ART initiation, the median patient age was 37 years and 65% were female. Overall, the baseline median CD4 cell count was 141 cells per microliter. At 6 and 12 months after ART initiation, 92% and 86% of patients, respectively, remained on ART at their original site. By 6 months, 3.6% were dead and 3.4% were lost to follow-up; by 12 months, 4.6% were dead and 4.9% were lost to follow-up. Among patients with available follow-up CD4 cell count data, median CD4 cell counts increased by 98 cells per microliter and 119 cells per microliter at 6 and 12 months after ART initiation, respectively. CONCLUSIONS: Rwanda's national ART program achieved excellent 6- and 12-month retention and immunologic outcomes during the first 2 years of rapid scale-up. Routine supervision is required to improve compliance with clinical guidelines and data quality. |
| | |
Authors:
|
David W Lowrance; Francois Ndamage; Eugenie Kayirangwa; Felix Ndagije; Wilson Lo; Donald R Hoover; Jeff Hanson; Batya Elul; Aliou Ayaba; Tedd Ellerbrock; Alphonse Rukundo; Fabienne Shumbusho; Denis Nash; Jules Mugabo; Anita Assimwe |
Related Documents
:
|
19209067 - Failure of immunologic criteria to appropriately identify antiretroviral treatment fail... 12140037 - Treatment of conjunctival papillomata with topical interferon alfa-2b. 15920347 - Prediction of treatment outcome in chronic hepatitis c patients based on early viral dy... 17955437 - Impact of hiv-1 reverse transcriptase polymorphism f214l on virological response to thy... 21831787 - Lactobacillus johnsonii crl1647, isolated from apis mellifera l. bee-gut, exhibited a b... 20581317 - Role of esophageal stents in the nutrition support of patients with esophageal malignancy. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of acquired immune deficiency syndromes (1999) Volume: 52 ISSN: 1525-4135 ISO Abbreviation: J. Acquir. Immune Defic. Syndr. Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-25 Completed Date: 2009-09-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100892005 Medline TA: J Acquir Immune Defic Syndr Country: United States |
Other Details:
|
Languages: eng Pagination: 49-55 Citation Subset: IM; X |
Affiliation:
|
Global AIDS Program, US Centers for Disease Control and Prevention, Kigali, Rwanda. lowrance@rw.cdc.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count Cohort Studies Developing Countries Female HIV Infections / drug therapy*, immunology*, virology HIV-1* Humans Male Middle Aged Multivariate Analysis Program Evaluation / statistics & numerical data* Protease Inhibitors / therapeutic use Retrospective Studies Reverse Transcriptase Inhibitors / therapeutic use Rwanda Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Protease Inhibitors; 0/Reverse Transcriptase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART...
Next Document: Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vac...